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2352-3042/Copyright ª 2014, ChongqiAbstract Recent progress in using stem cells for tissue repair and functional restoration has
aroused much attention due to its potential to provide a cue for many diseases such as myocar-
dial infarction. Stem cell therapy for cardiovascular disease has been studied extensively at
both experimental and clinical levels. Pluripotent stem cells and mesenchymal stem cells were
proven to be effective for myocardial regeneration, angiogenesis, and cardiac functional
restoration. In this review, we will concisely discuss advantages and disadvantages of
currently-used stem cells for cardiovascular repair and regeneration. The limitations and
uniqueness of some types of stem cells will also be discussed. Although substantial progress
has been made over the last decade about stem cells in cardiovascular regeneration, many
challenges lie ahead before the therapeutic potentials of stem cells can be fully recognized.
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sources and health budgets are promised in the near
future.3 Therefore, there is an urgent need to develop
more effective therapeutic approaches for cardiovascular
disease. The emerging of cardiovascular regenerative
medicine may provide an encouraging direction for future
therapeutics, which focuses on replacing or regenerating
damaged myocardium and blood vessels to restore or
establish normal cardiac function.4 Great advantages exist
in this new treatment compared to traditional therapy,
which was considered only palliative strategy. Traditional
cardiac therapy are effective in resolving the acute pro-
cesses of the disease and extending the patient’s lifespan,
however, it does not provide the patients a cure, but rather
leaving them with chronic diseases as sequelae.5 In
contrast, cardiovascular regenerative medicine makes it
possible to replace damaged myocardial cells with the
patient-specific pluripotent stem cell-derived cardiac
myocytes, avoiding the aforementioned medical problems,
and prevents or reverses the disease development.4 More-
over, most of the pluripotent stem cells, except for em-
bryonic stem cells, are derived from the patients and
possess the same genotype and phenotype, and thus are
significantly valuable tools for studying the molecular
mechanisms of the disease and for developing patient-
specific therapy.6 Stem cell therapy has demonstrated
beneficial effects on several cardiovascular diseases
including ischemic heart disease,7,8 heart failure,9 endo-
thelial dysfunction,10,11 peripheral artery disease,12,13
atherosclerosis,14 and pulmonary hypertension15,16 (Fig. 1).
Stem cells have potential to differentiate into several
specific types of cells. Based on the source of origin, stem
cells can be classified into embryonic stem cells (ESCs) and
adult stem cells (ASCs), where the former comes from
embryos and the latter originates from mature adults.17
Furthermore, the ASCs can be divided into tissue-specific
stem cells and bone marrow-derived stem cells (BMCs).
Bone marrow contains at least two types of stem cells:
hematopoietic stem cells (HSCs) and mesenchymal stem
cells (MSCs), and endothelial progenitor cells (EPCs) can
also be found in the bone marrow.18 In this review, we will
summarize the properties of different types of stem cells
and their regenerative capabilities to restore or repair Stem Cell 
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Fig. 1 Potential stem cell therapy for major cardiovascular
disorders.cardiac structure and function. We will also discuss selec-
tion and acquisition of stem cells and evaluation of effec-
tiveness of stem cell therapy for cardiovascular disease.
Pluripotent stem cells
The goal of cardiac stem cell therapy is to restore or
regenerate myocardium. The challenge was to identify a
suitable source for generating sufficient and phenotypically
confirmed cardiomyocytes. Over the past decade, rapid
progress has been made in identification, derivation, and
characterization of stem cells or progenitor cells. Among
these, the embryonic stem cells (ESCs) have attracted
attention due to their unique properties.6 ESCs are plurip-
otent stem cells which are derived from the inner cell mass
of the blastocyst-stage embryo.19 Specifically, these cells
remain in an undifferentiated state in culture for a long
period but retain the potential to differentiate into all cell
types in the human body, including cardiomyocytes. Human
ESCs (hESCs) were isolated by Thomson et al e more than a
decade after the first isolation of mouse ESCs (mESCs) in
1981.20,21 Since then, the potential for using these unend-
ing multipotent cells to treat congenital and degenerative
diseases has aroused great interest. Theoretically, the
hESCs are capable to differentiate into all three germ
layers-endoderm, ectoderm, and mesoderm, so it is
important to investigate the signaling pathways and tran-
scription factors that direct its specific differentiation
process.19 From a large number of studies, researchers have
identified several signaling molecules that are involved in
early cardiac differentiation. Over-expression of tran-
scriptional factors such as GATA4, Nkx2-5, or MEF2C can
induce differentiation of hESCs into cardiomyocytes
(Fig. 2), while inhibition of these factors halts the forma-
tion of cardiomyocytes.22 Other factors like growth factors
TGFb1 and FGF2, cardiotrophin, reactive oxygen species
(ROS), and dimethyl sulfoxide (DMSO) might also affect the
differentiation process.23,24
Despite the exciting achievements of hESCs-
differentiated cardiomyocytes in both murine and human
models, several pressing issues limit its clinical application.
First of all, hESCs research has raised some serious ethical
problems due to the fact that the establishment hESCs
required the destruction of early human embryos, which
was considered crimes against humanity.21 Additionally, the
ESCs are generated from embryos and do not retain the
same genome with the patients, thus has potential risk of
immune rejection after transplantation.6 Furthermore,
grafted ESCs in mice only generated a minor population of
cardiomyocytes, which was even less in the human model.25Fig. 2 Effects of transcription factors on hESC differenti-
ation. Over-expression of key transcriptional factors such as
GATA4, Nkx2-5, or MEF2C leads to differentiation of human
embryonic stem cells (hESCs) into cardiomyocytes. Inhibition
of these transcription factors maintain hESC pluripotency.
Table 1 Comparison of advantages and limitations of different types of stem cells.
Stem cell type Limitations Advantages
Embryonic stem cells (1) Ethical dilemmas
(2) Possible immune rejection after
implantation
(3) Only a small number of differenti-
ated cardiomyoctes can be
generated
(4) May lead to teratocarcinomas
(5) Genetic instability
Can differentiate into cells of all three germ
layers
Pluripotent stem cells (1) Genetic instability
(2) More research is needed before using
for cardiovascular repair/
regeneration
Avoids ethical concerns
Adult stem cells (1) Natural regeneration capacity of
CSCs are too limited
(2) Acquisition and isolation difficulties
(3) More research needed
(1) Avoids ethical concerns
(2) Lower risk of immune rejection
Mesenchymal stem cells More research needed (1) Allow for allogenic grafting without the use
of immunosuppressive agents
(2) Can self-renew, proliferate, and
differentiate
(3) Promote growth of adjacent cells
(4) Less susceptible to mutations
(5) Easy to collect
Hematopoietic stem cells (1) High maintenance
(2) Low frequencies
(3) Unknown signaling pathways
(1) Proliferate and migrate to injury site in
response to physiological/pathological
stimuli
(2) Capable of myogenesis and angiogenesis
Endothelial progenitor cells Extremely low numbers in peripheral
blood and bone marrow makes ex vivo
expansion difficult
Increase its numbers in response to ischemia/
cytokine stimuli and can migrate to injury site
and differentiate into new myocytes
Stem cells and cardiovascular repair 115Since the number of differentiated cardiomyocytes signifi-
cantly compromises the ultimate success of future cell-
grafting procedures, strategies to enhance the generation
of myocytes by ESCs is of crucial importance. Finally,
in vivo implantation of hESCs gave rise to formation of te-
ratocarcinomas (Table 1), although the malignant tumori-
genic potential of ESCs is not well defined yet, this finding
raises concerns about the safety of its clinical use.26
In contrast, the use of human inducible pluripotent stem
cells (hiPSCs) overcomes the limitations and ethical con-
cerns of hESCs (Table 1).27 The hiPSCs are derived by
reprogramming somatic cells to a pluripotent state.28,29
Several research teams have compared hESCs and hiPSCs
and their differentiated progeny. Laurent et al reported
that both hESCs and hiPSC demonstrate similar degree of
genomic instability,30,31 suggesting that much investigation
is needed before evaluating their potential for cardiovas-
cular repair and regeneration. Other groups reported that
the ability of hESCs and hiPSCs to differentiate into car-
diomyocytes is different.32,33 Parthenogenetic genetic stem
cells, another class of pluripotent stem cells, may also
avoid disadvantages of hESCs with possibility of reduced
immune rejection.27 Didie et al showed that mouse
parthenogenetic stem cell-derived cardiomyocytes inte-
grated electrically with host myocardium and improved
cardiac function in a mouse model of myocardialinfarction.34 Table 1 summarizes the limitations and ad-
vantages of using different types of stem cells for cardio-
vascular therapy.Adult stem cells
As discussed above, there are political, ethnical and tech-
nical concerns in clinical application of hESCs. Recent ad-
vances in adult stem cell research might offer a promising
advanced alternative for cell-based therapies.4 The use of
adult stem cells avoids the ethical and religious fights
triggered by hESCs; they possess the same genotype of the
patient since they are isolated from adults, thus minimizing
the risk of immune rejection (Table 1).35 For all these
reasons, the adult stem cells seem more applicable to be
used in cell-based cardiovascular repair and regeneration.
The heart was previously considered a terminally differ-
entiated organ without the capacity for self-renewal.
However, recent evidence suggests the existence of
endogenous cardiac stem cells (CSCs) that are able to
generate new myocytes and blood vessels.36 Typically, only
a small number of CSCs cells (one for every 1  103 myo-
cytes) are distributed in the atria, ventricles, and epicar-
dium. In physiological conditions, CSCs are inactive and
exiting cell cycle, with only 2e3% actively differentiated
116 Q. Sun et al.for normal myocardial turnover. However, most of the CSCs
can be activated and differentiated into new myocytes or
vascular cells in response to pathological or physiological
stimuli such as ischemia or cellular damage.37 Although
some experiments demonstrated that injection of CSCs can
generate new myocardium to replace the cells lost in MI,36
the natural regeneration capacity of CSCs are too limited to
be used in clinical therapy, and therefore required ex vivo
expansion (Table 1).38 There is great advantage to use this
organ origin stem cell for myocyte replacement and repair
as long as it has been effectively stimulated. However,
major difficulties exist in the acquisition and isolation of
CSCs from myocardial samples, reducing available CSCs to
be used for implantation.35 Furthermore, the molecular
mechanism that regulates the CSCs proliferation and dif-
ferentiation into myocardium has not been elucidated.
Despite numerous publications, no consensus has been
reached on the identity and actual regenerative or renewal
effects of CSCs. Thus, the application of CSCs in cardio-
vascular disease will remain difficult until all these limita-
tions are appropriately addressed. In addition, attention
and effort should be paid to restoration of the fibroblasts
function which provides a favorable environment for repair
and regeneration of cardiomyocytes.Mesenchymal stem cells
Mesenchymal stem cells (MSCs) were reported by Frieden-
stein et al who identified a sub-population of bone marrow
cells that adhered to plastic and demonstrated fibroblast-
like properties.39 MSCs have potential to differentiate into
a variety of mesoderma lineage cells (e.g., osteoblasts,
adipocytes, and cadiomyocytes).40,41 Therefore, MSCs, also
termed bone marrow stromal cells, are pluripotent pro-
genitor cells of bone marrow origin.42 Human MSCs have
distinct surface markers from hematopoietic stem cells:
CD105 (SH2), SH3, Stro-1, and CD13.43 MSCs are considered
immunologically privileged stem cells due to their lack of
surface markers (antigens) required for activation of T
lymphocytes.40 In an MHC-mismatched rat heart trans-
plantation model, MSCs can induce tolerance and long-term
graft acceptance.44 It was reported that the immunosup-
pressive effect of MSCs may be mediated by inhibiting the
maturation of dendritic cells and suppressing the function
of T, B, and natural killer cells.41,45 Interestingly, trans-
planted MSCs also secrete paracrine factors to regulate the
immune system and modulate inflammatory responses.40
These unique features make MSCs attractive for future
regenerative medicine such as tissue repair and gene de-
livery, allowing allogenic grafting without the use of
immunosuppressive agents (Table 1).
MSCs are an ideal source of replacement cells because of
their potential for self-renewal, proliferation and differ-
entiation.46e48 It was shown that human MSCs injected into
the left ventricle of an adult mouse heart effectively
engrafted in the myocardium and differentiated into car-
diomyocytes that were morphologically indistinguishable
from the native cardiomyocytes.49 Notably, MSCs also pro-
mote the growth and proliferation of adjacent cells via
their paracrine function.41 Although MSCs are known to
secrete a variety of regulatory and trophic factors includinggrowth factors, cytokines, and chemokines, the nature of
the secretome remains to be determined.50 MSCs can enter
the circulation and follow chemotactic gradients to home
to sites of injury or inflammation participating in wound
healing and tissue repair via its regenerative and paracrine
function.51e54 In addition, MSCs also have other charac-
teristics that facilitate their clinical application, such as
their expansion potential, ease of collection, and
decreased susceptibility to genetic mutations during
in vitro passages.55 As a guide for future directions, MSCs
engineered with desired therapeutic genes may expand and
enhance their therapeutic potentials.
Hematopoietic stem cells
Hematopoietic stem cells (HSCs) are the foundation of
adult hematopoiesis and give rise to all types of blood cells
throughout the lifespan.56 HSCs are of clinical significance
in bone marrow transplantation for the treatment of
blooderelated genetic deficiency and leukemia.57,58 HSCs
are defined as multipotent stem cells, which have the ca-
pacity to differentiate into a number of cells, including
cardiomyocytes and endothelial cells.38 HSCs can be iso-
lated from the bone marrow as well as the peripheral
blood, but its circulating forms are much lower than in the
bone marrow.17 In the normal condition, the number of
quiescent HSCs is limited in the bone marrow (one for every
1  104 bone marrow cells).17 In response to physiological
or pathological stimuli, these stem cells can quickly pro-
liferate and mobilize from their resident bone marrow to
peripheral circulation, and then migrate to the site of
injury.18 Murine progenitor cells do not have specific sur-
face markers, whereas human HSCs express surface
markers: CD34 and AC133, which can be used for positive
selection and isolation.59 By characterization of CD34þ-
CD38- phenotype stem cells, researchers found that blood
from the human umbilical cord is a relatively abundant
source of HSCs.60 Moreover, highly purified CD34þ-CD38-
hematopoietic progenitors were also isolated from human
fetal livers.61 It was reported that HSCs could result in
cardiomyocyte generation via myeloid intermediates by
fusion-dependent mechanism.62 The employment of
myeloid derivatives as donor cells may provide more
effective cell-based therapy for cardiac repair.62 The
advantage of using HSCs in cardiovascular repair underlies
that they potentially fulfill the goals required for stem cell
transplantationdmyogenesis and angiogenesis (Table 1).
However, their low frequencies, difficult maintenance in
cell culture, as well as the unknown signaling pathways that
regulate the HSCs proliferation and differentiation, must be
addressed.17 In addition, specific induction of HSCs into
cardiomyocytes must be guaranteed to avoid
tumorigenesis.
Endothelial progenitor cells
Endothelial progenitor cells (EPCs) and their derivatives
have been reported to have therapeutic potential for car-
diovascular disease.11 EPCs were reported in 1997 by Asa-
hara et al who showed that purified CD34þ hematopoietic
progenitor cells from adults can differentiate into
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esis.63 Although originated in the bone marrow, EPCs can
also be found in the peripheral blood and human umbilical
cord blood.18 EPCs share two surface antigens with HSCs,
CD34 and the VEGF receptor Flk-1, and double labeling of
these two markers can be used for positive selection of
highly homogenous EPCs populations.38 Under normal con-
dition, the number of EPCs is extremely low in the pe-
ripheral blood and bone marrow, which makes it difficult
for the ex vivo expansion of sufficient EPCs required for
clinical applications.17 EPCs are angiogenic cells that
mobilized in response to ischemia or exogenous cytokines
which further guide EPCs homing into sites of ischemic
tissue, and thus participate in the repair and maintenance
of vascular homeostasis (Table 1).38 It was reported that
EPCs have proliferative potential and play a vital role in
vascular regeneration by replacing or restoring damaged
endothelial cells.64 In the field of cardiac research, EPCs
are found to increase its circulating numbers in response to
myocardial ischemia or cytokine stimuli, homing to the site
of myocardium injury and possibly differentiating into new
myocytes.65,66 EPCs have the capacity to circulate, prolif-
erate and differentiate into mature endothelial cells but
have neither acquired mature endothelial markers nor
formed a lumen.67 It was reported that transplanted
autologous EPCs improved mean pulmonary artery pres-
sure, cardiac output and pulmonary vascular resistance in a
dog model of pulmonary hypertension.68
Technical challenges of using stem cells for
cardiovascular repair
To select appropriate stem cells for cardiovascular tissue
regeneration and functional repair, the following issues
might be considered: 1) acquisition of adequate stem cells,
2) ex vivo expansion efficiency, 3) the optimal approach of
administration, 4) In vivo differentiation efficiency and
functional integration.
Acquisition of adequate stem cells
It is challenging for acquisition of adequate ESCs due to
limitations as discussed above. In contrast, isolation of
BMCs such as hematopoietic, mesenchymal, or endothelial
progenitor stem cells are relatively easier because they can
be collected either from the peripheral blood or bone
barrow. In addition, the organ-originated stem cells such as
CSCs may also be difficult to collect because of their unique
location and limited number of stem cells.
Ex vivo expansion efficiency
The ex vivo expansion and purification of specific sub-
populations are required to facilitate their utilization
because the number of stem cells from direct in vivo
isolation is limited. Moreover, for ESCs, in vitro pre-
differentiation can help prevent the risk of teratoma for-
mation.69 The stimulation methods for optimal expansion
and specific selection vary with cell types. For instance,
administration of exogenous cytokines is often used tofacilitate the differentiation of ESCs to specific cells.55
Flowcytometry is used for positive selection of new car-
diomyocytes. The common cardiac markers for fluorescent
labeling include GATA4, Nkx2.5, a-MHC, b-MHC, and ANP.19
Another popular method to track the generation of car-
diomyocytes is encoding target gene with enhanced green
fluorescent protein (GFP). The subsequent sorting of the
GFP-positive cells yields a high level of purified myocyte
subpopulation.55 The selected cells must be screened to
ensure functional properties of cardiomyocytes before
transplantation. The myocytes should have automaticity
and exhibit action potentials. The early myocytes may show
immature AP properties, but the functional maturity is
expected with prolonged duration in culture.
Optimal administration approach
Three approaches have been tested for delivery of stem
cells to the cardiovascular system (intravenous vs. intra-
coronary vs. intramyocardial). Stem cell transplantation
into heart can be carried out via the intracoronary route or
coronary sinus, or directly administered to the site within
myocardium using endocardial mapping devices.38 More-
over, bone marrow-derived cells can be administered
intravenously, and homing of these cells to sites of injured
myocardium can be confirmed using specific markers.55 To
determine the best administration approach for candidate
stem cells, it is necessary to test and compare all three
delivery methods in an animal model of MI. Thus, the
maximal homing rate of stem cells to the site of injured
heart in conjunction with the most efficient approach for
delivery (e.g. intravenous) can be selected as the optimal
approach for future clinical transplantation. The delivery of
stem cells into the pulmonary circulation via jugular veins is
selected as an effective approach for the treatment of
pulmonary arterial hypertension.
In vivo differentiation efficiency and functional
integration
Several clinical trials indicated that the implanted stem
cells may not be able to function as competent myocytes.
The improvement of cardiac function may be due to other
possibilities, including activation of resident myocyte
function or amplification of the endogenous repair process
via the paracrine effect mediated by transplanted
cells.19,35 The structural and functional characteristics of
stem cell-derived cardiomyocytes, and their ability to
integrate into the host tissue, will need to be evaluated.
First, the structural proteins in mature myocytes such as
sarcomeric organization, e.g., a-actin, cardiac troponins,
myosin heavy chain, myosin light chain, desmin, and
tropomyosin, need to be confirmed. Second, the electro-
physiological studies should be performed to study the ion
channels and propagation of action potential in stem cell-
derived cardiomyocyte. Furthermore, other parameters
(e.g., the intracellular calcium) that depict normal myo-
cyte function should also be examined.70 In addition,
whether gap junctions are present between host and donor
cardiomyocytes, and whether the electromechanical and
structural integration have been formed between host and
118 Q. Sun et al.donor cardiomyocytes need to be examined. Finally, to
assess whether stem cell transplantation can restore,
maintain, or improve impaired heart function, it is neces-
sary to assess clinical parameters such as cardiac pump
function, coronary blood flow, cardiac remodeling, and
cardiac oxygenation. Vascular endothelial function can be
assessed by in vivo blood pressure responses to endothelial-
derived vasodilators. The long-term therapeutic effect also
need to be monitored to determine whether this treatment
improves lifespan and decreases mortality. Lastly, the po-
tential side effects of stem cell therapy must be fully
evaluated to guide future clinical application.
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